Document Detail

Remicade as TNF suppressor in patients with myelodysplastic syndromes.
MedLine Citation:
PMID:  15370256     Owner:  NLM     Status:  MEDLINE    
Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low-risk myelodysplastic syndromes (MDS) patients in two cohorts; 5 and 10 mg/kg intravenously every 4 weeks for 4 cycles. Median age was 68 years, 33 had primary MDS, 14 had refractory anemia (RA), 14 RA with ringed sideroblasts, 9 RA with excess blasts. Nine patients stopped therapy prior to completing 4 cycles, 3 from cohort 1 and 6 from cohort 2 and response was evaluated using the International Working Group criteria in 28 patients who completed the 4 cycles. Six patients showed disease progression, 14 had stable disease and 8 showed hematologic responses, 3/15 (20%) in cohort 1 and 5/13 (38%) in cohort 2. Two patients had multi-lineage responses, 2 had > 100% increase in absolute neutrophils, 1 had > 1 gm/dl increase in hemoglobin, 1 had reduction in blasts from 7% to 1%, and 2 had minor cytogenetic responses (> 50% reduction in + 8 and 20q-metaphases respectively). We conclude that Remicade may have a variety of activities in low risk MDS patients, is well tolerated with a high patient compliance, and may be considered for combination therapy in the future.
A Raza; A Candoni; U Khan; L Lisak; S Tahir; F Silvestri; J Billmeier; M Imran Alvi; M Mumtaz; S Gezer; P Venugopal; P Reddy; N Galili
Related Documents :
19772796 - Poor to modest agreement between rheumatoid arthritis response measures in clinical pra...
11704286 - Hla-drb1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and he...
3437426 - Retropharyngeal hematoma as a new cause of acute upper airway obstruction in rheumatoid...
17896806 - Bone mineral density in older adult patients with rheumatoid arthritis: an analysis of ...
18280636 - Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries.
11299066 - The acute effects of body position strategies and respiratory therapy in paralyzed pati...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  45     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-16     Completed Date:  2005-04-19     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  2099-104     Citation Subset:  IM    
Section of Myeloid Diseases, Rush University, Chicago, IL 60612-3515, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Refractory
Antibodies, Monoclonal / administration & dosage*,  toxicity
Chromosome Aberrations
Cytogenetic Analysis
Disease Progression
Myelodysplastic Syndromes / complications,  drug therapy*,  genetics
Pancytopenia / drug therapy
Patient Compliance
Pilot Projects
Remission Induction
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Grant Support
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bcl-2 and immunoglobulin gene rearrangements in patients with malaria related chronic splenomegaly.
Next Document:  Mutational analysis of IgVH and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B...